The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1476
A New Subcutaneous Immune Globulin (HyQvia) for Primary Immunodeficiency
The full article is available to subscribers Subscriber Login   

Immune globulin (IgG) has been available for administration intravenously once every 3-4 weeks or subcutaneously once daily, once weekly, or every 2 weeks for treatment of primary immunodeficiencies. Now the FDA has approved human immune globulin 10% with recombinant human hyaluronidase (HyQvia – Baxter) for subcutaneous administration only every 3-4 weeks in adults with these disorders. The IgG component of HyQvia is identical to Gammagard Liquid, which was approved in 2005 for IV administration and in 2011 for SC administration.

PRIMARY IMMUNODEFICIENCY — Primary immunodeficiencies include common variable immunodeficiency (CVID), X-linked or congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.1 These disorders are usually congenital or develop in early childhood, but may also develop later ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: A New Subcutaneous Immune Globulin (HyQvia) for Primary Immunodeficiency
Article code: 1476b
 Electronic, downloadable article - $25